Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.8% in the 4th quarter, Holdings Channel reports. The fund owned 40,572 shares of the medical research company’s stock after selling 5,944 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Charles River Laboratories International were worth $7,490,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in Charles River Laboratories International by 6.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock valued at $101,483,000 after acquiring an additional 32,311 shares during the period. Raymond James Trust N.A. acquired a new stake in Charles River Laboratories International during the 3rd quarter worth $211,000. Cerity Partners LLC grew its holdings in shares of Charles River Laboratories International by 65.9% during the third quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company’s stock worth $963,000 after buying an additional 1,943 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in Charles River Laboratories International by 12.6% in the 3rd quarter. Daiwa Securities Group Inc. now owns 6,355 shares of the medical research company’s stock valued at $1,252,000 after acquiring an additional 710 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Charles River Laboratories International by 0.9% during the 3rd quarter. Fisher Asset Management LLC now owns 184,692 shares of the medical research company’s stock worth $36,379,000 after purchasing an additional 1,586 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Charles River Laboratories International

In related news, CEO James C. Foster bought 6,075 shares of the stock in a transaction dated Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of several analyst reports. Bank of America reduced their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. UBS Group restated a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. cut their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $189.77.

Charles River Laboratories International Trading Down 3.2 %

NYSE CRL opened at $161.57 on Wednesday. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $273.32. The firm’s fifty day moving average is $165.32 and its two-hundred day moving average is $183.30. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm has a market cap of $8.26 billion, a PE ratio of 1,077.13, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.46 earnings per share. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).